MTPConnect Launches New Investment Round for Medtech Innovators
MTPConnect has opened a new round of investment through its Targeted Translation Research Accelerator (TTRA) to fund Australian medical technology innovators.
Targeting Critical Health Areas
The initiative specifically targets companies developing medical devices for the prevention, diagnosis, treatment, or management of cardiovascular disease and diabetes.
Eligibility and Funding
Australian small and medium enterprises, including start-ups and research spin-offs, are invited to submit expressions of interest.
Eligible companies can apply for up to $1 million in non-dilutive funding, which requires a matching cash co-contribution.
Submissions for this round close on March 30, 2026.
MTPConnect Chief Executive Officer Stuart Dignam stated that access to capital is a significant barrier for early-stage medtech companies, particularly in device development. The TTRA program has previously invested in 34 projects.
Strategic Support Beyond Capital
Beyond financial support, participating companies gain access to MTPConnect's internal specialists and a network of local and international industry partners.
This network provides crucial guidance on commercial strategy, regulatory pathways, and clinical validation, enhancing the likelihood of market success.
Webinar and Program Vision
The TTRA program is supported by the Australian Government's Medical Research Future Fund.
An information webinar for prospective applicants will be hosted by MTPConnect on March 4, 2026, to provide further details and answer questions.
The TTRA initiative aims to connect scientific discovery with commercial deployment, backed by a $75.5 million investment pool. It combines milestone-based funding with expertise in regulatory, clinical, and market aspects, bridging the gap between innovation and impact.